Patents by Inventor Qing Shi

Qing Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10106559
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: October 23, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Publication number: 20180302335
    Abstract: An approach is provided for orchestrating computing resources between different computing environments. Data from first and second computing environments is monitored. The data specifies utilization of infrastructure, middleware, software testing tools, integrated development environments (IDEs), relationships among nodes, utilization of the nodes, and user behavior in the first and second computing environments. Based on the utilization of the infrastructure, middleware, tools, IDEs, node relationships and utilization, and user behavior, a pattern decision tree is updated. Based on the updated pattern decision tree and a user request that specifies requirements of the computing resources, an orchestration topology is generated that specifies a placement of the computing resources in the first and second computing environments.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 18, 2018
    Inventors: Xue Feng Gao, Hui Qing Shi, Qing Feng Zhang, Zhi Feng Zhao
  • Publication number: 20180258507
    Abstract: A steel plate having excellent resistance to fatigue crack growth and manufacturing method thereof, wherein the components of the steel plate in weight percentage are: 0.040-0.070% of C, 0.40-0.70% of Si, 1.30-1.60% of Mn, less than or equal to 0.013% of P, less than or equal to 0.003% of S, less than or equal to 0.30% of Cu, less than or equal to 0.30% of Ni, less than or equal to 0.10% of Mo, 0.008-0.018% of Ti, 0.015-0.030% of Nb, less than or equal to 0.0040% of N, 0.0010-0.0040% of Ca, and the balance being Fe and inevitable impurities. By controlling [% C]×[% Si] between 0.022-0.042, {([% C]+3.33[% Nb])×[% Si]}×Vcooling rate/Tcooling-stopping between 1.15×10?4˜2.2×10?3, carrying out a Ca treatment, and Ca/S=1.0-3.0 and (% Ca)×(% S) 0.28?1.0×10?3, the optimizing the TMCP process, the finished steel plate has a microstructure which a duplex-phase structure of ferrite+uniformly and dispersedly distributed bainite and has an improved resistance to fatigue crack growth.
    Type: Application
    Filed: November 4, 2015
    Publication date: September 13, 2018
    Applicant: BAOSHAN IRON & STEEL CO., LTD.
    Inventors: Zicheng Liu, Qing Shi
  • Publication number: 20180244021
    Abstract: A multi-layer film comprising: a) a first layer comprising i) a polyolefin component; and ii) a polyethylene oxide/polyethylene copolymer having a Hydrophile-Lipophile Balance value in the range of from 2 to 6; b) a second layer comprising i) a polyolefin component; ii) from 1 to 5 weight percent of an additive selected from the group consisting of sorbitan esters, polyoxyethylene esters, glycerol esters, polyglycerol esters, fluorine-based compounds and combinations thereof, wherein the additive has a Hydrophile-Lipophile Balance value in the range of from 7 to 18; and iii) an inorganic filler; wherein the second layer is adjacent to the first layer and c) a skin layer comprising a polyolefin component, is disclosed. The multi-layer film is used in greenhouse applications.
    Type: Application
    Filed: September 18, 2015
    Publication date: August 30, 2018
    Inventors: Qing Shi, Hongyu Chen, Daojin Hang, Libo Du, Andong Liu, Yong Chen
  • Publication number: 20180230280
    Abstract: A film comprising, consisting of, or consisting essentially of: a) a polyolefin component; b) an additive comprising i) a first polyethylene oxide/polyethylene copolymer having a HLB value in the range of from 1 to 7 and a structure selected from the group consisting of CH3CH2(CH2CH2)aCH2CH2(OCH2CH2)bOH and CH3CH2(CH2CH2)aCO(OCH2CH2)bOH wherein a is from 9 to 25 and b is from 1 to 10; and ii) a second polyethylene oxide/polyethylene copolymer having a HLB value in the range of from 7 to 18 and a structure selected from the group consisting of CH3CH2(CH2CH2)aCH2CH2(OCH2CH2)bOH and CH3CH2(CH2CH2)aCO(OCH2CH2)bOH wherein a is from 9 to 25 and b is from 1 to 10, is disclosed. The film is used in greenhouse applications.
    Type: Application
    Filed: September 18, 2015
    Publication date: August 16, 2018
    Inventors: Qing Shi, Hongliang Zhang, Hongyu Chen, Hong Zheng, Yong Chen
  • Patent number: 10023576
    Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: July 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A. M. Cornelius, T. G. Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino
  • Publication number: 20180117024
    Abstract: The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 3, 2018
    Inventors: Robert Garfield, Shao-Qing Shi, Leili Shi
  • Publication number: 20180093112
    Abstract: Methods and apparatuses for speeding the softening of the cervix (cervical ripening) by way of application of ultrasound energy. A vaginal transducer may be used to emit pulse-modulated ultrasound energy directed to the cervix. Focused ultrasound energy may be applied transabdominally and directed at the cervix.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Inventors: Bruce C. Towe, Robert E. Garfield, Shao-Qing Shi
  • Publication number: 20180079758
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 22, 2018
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Publication number: 20180057494
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, for use as a human PDE1 inhibitor.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 1, 2018
    Inventors: Mark David Rekhter, Qing Shi
  • Patent number: 9872983
    Abstract: Systems and methods for producing cervical ripening in a pregnant patient. The method includes generating an electrical stimulation current between about 0.01 milliamperes and about 6 milliamperes using a current unit, coupling an electrode probe to the current unit, and inserting the electrode probe transvaginally so that at least one electrode of the electrode probe is in contact with the patient's cervix. The method also includes applying the electrical stimulation current from the current unit through the electrode probe and the at least one electrode to the patient's cervix to produce ripening of the patient's cervix.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 23, 2018
    Assignee: Dignity Health
    Inventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi, William Maner
  • Publication number: 20180002358
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
  • Publication number: 20180000838
    Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 4, 2018
    Inventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi
  • Publication number: 20170355698
    Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    Type: Application
    Filed: October 21, 2015
    Publication date: December 14, 2017
    Inventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A.M. Cornelius, T.G.Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino
  • Publication number: 20170355707
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    Type: Application
    Filed: October 21, 2015
    Publication date: December 14, 2017
    Inventors: Rajeev S. Bhide, Douglas G. Batt, Robert J Cherney, Lyndon A.M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
  • Patent number: 9815859
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
  • Patent number: 9794075
    Abstract: An Ethernet device is disclosed that may reduce transient currents and/or power consumption while entering and exiting a low power mode by selectively powering-on and/or powering-off a number of transceiver components at different times (e.g., in a staggered manner). The transient currents and/or power consumption may be further reduced by assigning different quiet period durations to different transceiver chains, for example, to minimize the number of transceiver components that enter and/or exit the low power mode at the same time.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 17, 2017
    Assignee: QUALCOMM Incorporated
    Inventors: Qing Shi, Lingyun Cai, James Qian Zhang
  • Publication number: 20170283438
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 5, 2017
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • Patent number: 9608800
    Abstract: A method and apparatus of clock recovery is disclosed. A communications device matches the frequency of a local clock signal with the frequency of a transmit clock signal of a transmitting device based on a first set of signals received from the transmitting device during a low-speed information exchange. The low-speed information exchange may correspond to an autonegotiation operation, wherein each of the transmitting device and the communications device declares its communication capabilities to the other device. The communications device then determines a frequency offset to be applied to the local clock signal during a high-speed data communication with the transmitting device. During the high-speed communication, the communications device may apply the frequency offset to the local clock signal and match the phase of the receive clock signal with the phase of the transmit clock signal based on a second set of signals received from the transmitting device.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 28, 2017
    Assignee: QUALCOMM Incorporated
    Inventors: Qing Shi, Yahuan Liu, Robert Yongli Wen, James Qian Zhang